Natural Products From Traditional Chinese Medicine: Potential Therapeutic Agents in Cancer Therapy-Induced Cardiotoxicity.

IF 5.1 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S545216

Ruoyu Jin, Qianhui You, Chenshi Li, Na Zhao, Chengyao Jia, Chinying Koo, Weiwei Zhang, Baonian Liu, Kaijian Huang

{"title":"Natural Products From Traditional Chinese Medicine: Potential Therapeutic Agents in Cancer Therapy-Induced Cardiotoxicity.","authors":"Ruoyu Jin, Qianhui You, Chenshi Li, Na Zhao, Chengyao Jia, Chinying Koo, Weiwei Zhang, Baonian Liu, Kaijian Huang","doi":"10.2147/DDDT.S545216","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer therapy-induced cardiotoxicity (CTIC) is a serious and increasingly recognized cause of death and disability among cancer survivors. It frequently necessitates the withdrawal or dose reduction of effective anticancer drugs, limiting therapeutic options and affecting patient outcomes. While CTIC poses a major health risk, the precise cellular and molecular mechanisms responsible for this toxicity remain elusive, which complicates the development of preventive and therapeutic strategies. In recent years, natural products derived from Traditional Chinese Medicine (TCM) have gained attention as potentially beneficial agents for CTIC management. These TCM natural products consist of biologically active compounds that often act on multiple therapeutic targets, offering a comprehensive approach to mitigating cardiotoxicity during cancer treatment. This review aims to provide a concise overview of CTIC associated with various anticancer drugs and examine the emerging research on TCM natural products in reducing the cardiotoxic effects related to cancer therapies, highlighting areas where further investigation is needed. In addition, we also provide the challenges and coping strategies faced by basic research and clinical transformation of Chinese medicine monomers.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"7653-7680"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414463/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S545216","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer therapy-induced cardiotoxicity (CTIC) is a serious and increasingly recognized cause of death and disability among cancer survivors. It frequently necessitates the withdrawal or dose reduction of effective anticancer drugs, limiting therapeutic options and affecting patient outcomes. While CTIC poses a major health risk, the precise cellular and molecular mechanisms responsible for this toxicity remain elusive, which complicates the development of preventive and therapeutic strategies. In recent years, natural products derived from Traditional Chinese Medicine (TCM) have gained attention as potentially beneficial agents for CTIC management. These TCM natural products consist of biologically active compounds that often act on multiple therapeutic targets, offering a comprehensive approach to mitigating cardiotoxicity during cancer treatment. This review aims to provide a concise overview of CTIC associated with various anticancer drugs and examine the emerging research on TCM natural products in reducing the cardiotoxic effects related to cancer therapies, highlighting areas where further investigation is needed. In addition, we also provide the challenges and coping strategies faced by basic research and clinical transformation of Chinese medicine monomers.

Abstract Image

查看原文本刊更多论文

中药天然产物：癌症治疗引起的心脏毒性的潜在治疗剂。

癌症治疗诱导的心脏毒性（CTIC）是癌症幸存者死亡和残疾的一个严重原因，并且越来越被认识到。它经常需要停药或减少有效抗癌药物的剂量，限制治疗选择并影响患者的预后。虽然CTIC对健康构成重大风险，但导致这种毒性的确切细胞和分子机制仍然难以捉摸，这使得预防和治疗策略的发展变得复杂。近年来，从中药中提取的天然产物作为潜在的有益制剂受到了关注。这些中药天然产品由生物活性化合物组成，通常作用于多个治疗靶点，为减轻癌症治疗期间的心脏毒性提供了全面的方法。本文旨在简要概述CTIC与各种抗癌药物的关系，并对中药天然产物在降低癌症治疗相关的心脏毒性作用方面的最新研究进行综述，指出需要进一步研究的领域。此外，我们还提出了中药单体基础研究和临床转化面临的挑战和应对策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.